ANAPROX Drug Patent Profile

Which patents cover Anaprox, and what generic alternatives are available?

Anaprox is a drug marketed by Atnahs Pharma Us and is included in one NDA.

The generic ingredient in ANAPROX is naproxen sodium. There are forty-two drug master file entries for this compound. One hundred and thirty suppliers are listed for this compound. Additional details are available on the naproxen sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Anaprox

A generic version of ANAPROX was approved as naproxen sodium by CONTRACT PHARMACAL on January 13^th, 1997.

Summary for ANAPROX

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ANAPROX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Atnahs Pharma Us	ANAPROX	naproxen sodium	TABLET;ORAL	018164-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Atnahs Pharma Us	ANAPROX DS	naproxen sodium	TABLET;ORAL	018164-003	Sep 30, 1987	AB	RX	Yes	Yes

International Patents for ANAPROX

See the table below for patents covering ANAPROX around the world.

Country	Patent Number	Title	Estimated Expiration
United Kingdom	1301459
United Kingdom	1301450
Switzerland	536803	Verfahren zur Herstellung neuer Naphthylpropionsäuren
United Kingdom	1301445
Japan	S5616785
Switzerland	547247	VERFAHREN ZUR HERSTELLUNG VON 2-(6-METHOXY-2-NAPHTHYL)1-PROPANOL.

Supplementary Protection Certificates for ANAPROX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1411900	2011C/016	Belgium		PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214
1411900	300481	Netherlands		PRODUCT NAME: NAPROXEN EN ESOMEPRAZOL; NATIONAL REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: GB PL 17901/0263-001 20101105
1411900	2011/016	Ireland		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
0984957	CR 2012 00035	Denmark		PRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105
1411900	1190013-1	Sweden		PRODUCT NAME: NAPROXEN OCH ESOMEPRAZOL; NAT. REG. NO/DATE: MTNR 43248 20101203; FIRST REG.: GB PL 17901/0263 20101105
1411900	SPC/GB11/015	United Kingdom		PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105

Anaprox (Naproxen) Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Anaprox, the brand name for naproxen, is a nonsteroidal anti-inflammatory drug (NSAID) widely used for pain relief, osteoarthritis, rheumatoid arthritis, and gout. Its extensive application and patent expiration status position it as a mature product with established market presence. This analysis examines current investment prospects, market dynamics, and projected financial trajectory, emphasizing generic maturation, regulatory shifts, competitive landscape, and potential growth avenues.

---

What Is the Market Position and Investment Outlook for Anaprox?

Naproxen, under the brand name Anaprox, commands a significant share in the NSAID segment. As a non-exclusive, generic product with numerous competitors, the revenue streams primarily derive from volume sales rather than premium pricing. The global NSAID market is projected to grow at a CAGR of approximately 3.4% through 2030, reaching an estimated USD 6.36 billion by 2030 [1].

Key investment considerations:

• Patent expirations have diminished exclusivity, leading to price erosion.
• Established demand for pain management sustains stable revenue streams.
• Generic market saturation pressures margins.
• Potential growth lies in formulation innovation and expansion into emerging markets.

---

How Do Market Dynamics Impact Anaprox’s Commercial Viability?

Factor	Impact on Anaprox	Details
Patent Status	Negative	Patent expiry in early 2000s led to saturation with generics, compressing prices.
Generic Competition	Intensified	Over 20 generic manufacturers market naproxen globally.
Pricing Trends	Downward	Prices declined by approximately 25% post-patent expiry [2].
Regulatory Environment	Mixed	Streamlined approval pathways (e.g., ANDA filings) bolster generics, yet a tighter regulatory focus on NSAID safety influences market access.
Consumer Preference	Stable	Chronic pain sufferers and elderly preferring cost-effective NSAIDs maintain steady demand.
Market Entry Barriers	Low	Low; multiple competitors, price-focused strategy necessary.
Emerging Markets	Growth Opportunity	Expansion in Asia-Pacific, Latin America, where NSAIDs are used extensively and reimbursement is improving.

---

What Are the Financial Trajectories and Revenue Projections?

Parameter	Current Status (2022-2025)	Projected 2026-2030	Notes
Market Size (USD)	USD 4.2 billion (Global NSAID segment)	USD 6.36 billion (by 2030)	Cumulative growth at 3.4% CAGR.
Anaprox Share (Estimate)	15-20% (due to generic competition)	15% (stabilization)	As a mature product, market share is steady but competitive.
Average Price per Unit (USD)	USD 0.05	USD 0.03	20% decline driven by generics.
Annual Revenue (USD)	USD 80-100 million	USD 50-60 million	Declining margins but steady volume.
Profit Margin (%)	10-15%	8-12%	Margin compression due to price wars.
R&D & Patent Strategies	Minimal	Minimal	Focused on formulation improvements for niche markets.

Note: The revenue decline is offset by volume increases driven by growing usage in emerging markets and expanding indications.

---

Who Are the Major Competitors in the Anaprox Market?

Competitor	Market Share (Estimate)	Product Name	Notes
Pfizer	25-30%	Aleve (naproxen sodium)	Market leader with strong brand recognition.
Teva	15-20%	Generic naproxen	Largest generic manufacturer.
Mylan	10-15%	Generic naproxen	Extensive distribution network.
Sandoz	10%	Generic naproxen	Focused on emerging markets.
Others	25-40%	Various generics	Fragmented competitive landscape.

---

What Are the Potential Growth Strategies and Opportunities?

Formulation Innovations

• Develop slow-release formulations to cater to chronic pain management.
• Explore combination drugs (e.g., NSAID with gastro-protective agents).

Market Expansion

• Focus on emerging markets with increasing healthcare access.
• Partner with local distributors to capitalize on regional growth.

Regulatory and Patent Strategies

• Leverage regulatory pathways (e.g., ANDAs) to secure abbreviated approvals.
• Identify orphan or niche indications with less competition.

Data & Digital Initiatives

• Invest in real-world evidence studies to demonstrate safety in specific populations.
• Utilize data analytics for targeted marketing and supply chain optimization.

Manufacturing & Supply Chain

• Optimize cost efficiencies through contract manufacturing.
• Enhance supply chain resilience to mitigate geopolitical and logistical risks.

---

How Do Policy & Regulatory Changes Influence Anaprox?

Policy Element	Implication	Details
FDA ANDA Pathway	Accelerated generic approvals	Reduces time-to-market for competitors, increasing competition.
Pricing Regulations	Price controls in certain markets	Can restrict revenue potential, especially in healthcare systems with price caps.
Import Tariffs & Trade Policies	Impact supply chain costs	Tariffs on raw materials or finished goods influence profit margins.
OTC Conversion	Potential OTC switch	Could expand accessible market but erode prescription margins.
Safety & Labeling Regulations	Increase compliance costs	Stricter labeling on NSAID safety in vulnerable populations.

---

Comparison with Alternative NSAID Products

Parameter	Anaprox (Naproxen)	Ibuprofen	Celecoxib (Celebrex)	Diclofenac
Market Size (USD)	USD 200+ million	Similar	USD ~1 billion	Similar
Pricing (per dose)	USD 0.02-0.05	USD 0.01-0.03	USD 1-2	USD 0.05-0.10
Indications	Pain, arthritis, gout	Pain, fever	Arthritis, pain	Pain, inflammatory conditions
Safety Profile	GI risk at high doses	Well-characterized	Cardiac risk in some populations	GI and hepatic risks
Market Dynamics	Mature, price-competitiveness	Highly saturated	Niche, specialty drug	Fragmented, regional

---

Key Takeaways

• Market saturation and generic competition have suppressed Anaprox’s margins but sustain steady volume in mature markets.
• Emerging markets represent fruitful growth avenues due to rising healthcare access and affordability.
• Innovation opportunities, including formulations and combination therapies, could help differentiate products.
• Regulatory trends favor rapid generic approvals but impose safety labeling requirements, impacting market access.
• Pricing continues downward pressure, but cost efficiencies and supply chain optimization can mitigate margin erosion.
• Strategic partnerships in regions with expanding NSAID use are vital for future growth.

---

FAQs

Q1: Will Anaprox regain exclusivity or face new patents?
A1: Given that naproxen patents expired decades ago, the likelihood of new patents is minimal. Focus shifts from exclusivity to cost competition and formulation improvements.

Q2: How significant is the OTC market for Anaprox?
A2: While naproxen is available OTC in many regions (e.g., Aleve), switching prescription formulations to OTC may expand reachable consumer bases, potentially impacting revenue streams.

Q3: What are the key safety concerns affecting naproxen sales?
A3: NSAID-related gastrointestinal, cardiovascular, and renal risks influence prescribing practices and regulatory policies, potentially affecting sales in sensitive populations.

Q4: What are the main regulatory hurdles for generic naproxen?
A4: Demonstrating bioequivalence, complying with safety labeling updates, and navigating antibiotic and safety-related approvals are primary hurdles.

Q5: Which regions offer the most promising growth for Naproxen formulations?
A5: Asia-Pacific and Latin America pose significant opportunities due to increasing healthcare infrastructure, demand for affordable pain management, and regulatory easing.

---

References

[1] MarketResearch.com, "NSAID Market Forecast," 2021.

[2] IQVIA, "Generic Drug Price Trends," 2022.

Note: Data points are estimates based on industry reports and may vary with market fluctuations.

---

This comprehensive analysis aims to inform strategic investment decisions by providing clarity on Anaprox's market position, competitive landscape, financial outlook, and growth prospects.